Genetic testing in the contemporary diagnosis of cardiomyopathy

Current Heart Failure Reports

Volumn 10, Issue 1, 2013, Pages 63-72

  Sturm, Amy Curry ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Arrhythmogenic right ventricular cardiomyopathy; Cardiomyopathy; Dilated cardiomyopathy; Exome; Genetic; Genetic counseling; Genetic testing; Genome; Hypertrophic cardiomyopathy; Left ventricular noncompaction; Mutation; Restrictive cardiomyopathy; Variant

Indexed keywords

MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN BETA;

ARTICLE; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; FAMILY HISTORY; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUTATIONAL ANALYSIS; PHENOTYPIC VARIATION; PRACTICE GUIDELINE; RELATIVE; RESTRICTIVE CARDIOMYOPATHY; SUDDEN DEATH; VENTRICULAR NONCOMPACTION;

EID: 84873724796     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0124-6     Document Type: Article

References (66)

1. •• Hershberger RE, et al. Genetic evaluation of cardiomyopathy - a Heart Failure Society of America practice guideline. J Card Fail. 2009;15(2):83-97. This oft-cited practice guideline is the mainstay of genetic testing and clinical screening recommendations for the inherited cardiomyopathies.
2. Charron P, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2010;31(22):2715-26.
3. •• Ackerman MJ, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Hear Rhythm. 2011;8(8):1308-39. This is another important expert statement regarding genetic testing for inherited cardiomyopathies.
4. Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60(8):705-15.
5. Marian AJ. Phenotypic plasticity of sarcomeric protein mutations. J Am Coll Cardiol. 2007;49(25):2427-9.
6. Fowler SJ, Napolitano C, Priori SG. The genetics of cardiomyopathy: genotyping and genetic counseling. Curr Treat Options Cardiovasc Med. 2009;11(6):433-46.
7. Klaassen S, et al. Mutations in sarcomere protein genes in left ventricular noncompaction. Circulation. 2008;117(22):2893-901.
8. Kubo T, et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol. 2007;49(25):2419-26.
9. Satoh M, et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun. 1999;262(2):411-7.
10. •• Herman DS, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012;366(7):619-28. This highly impactful study showed that truncating mutations of the gene TTN are implicated in approximately 25 % of familial DCM and in 18 % of sporadic cases, which has important implications for clinical genetic testing for this condition.
11. Greaser ML. Stressing the giant: a new approach to understanding dilated cardiomyopathy. J Mol Cell Cardiol. 2009;47(3):347-9.
12. Taylor M, et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation. 2011;124(8):876-85.
13. Hershberger RE, et al. Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circ Heart Fail. 2009;2(3):253-61.
14. Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA. 2009;302(22):2471-6.
15. Wheeler M, et al. A new era in clinical genetic testing for hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2(4):381-91.
16. Maron BJ, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785-9.
17. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349(11):1064-75.
18. Konno T, et al. Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol. 2010;25(3):205-9.
19. Charron P, et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 1998;97(22):2230-6.
20. Niimura H, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338(18):1248-57.
21. Page SP, et al. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ Cardiovasc Genet. 2012;5(2):156-66.
22. Makhoul M, et al. Clinical spectrum in a family with tropomyosin-mediated hypertrophic cardiomyopathy and sudden death in childhood. Pediatr Cardiol. 2011;32(2):215-20.
23. Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med. 2010;12(11):655-67.
24. Grunig E, et al. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 1998;31(1):186-94.
25. Michels VV, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 1992;326(2):77-82.
26. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45(7):969-81.
27. Hershberger RE, Siegfried JD. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(16):1641-9.
28. Sen-Chowdhry S, et al. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med. 2010;61:233-53.
29. Marcus FI, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31(7):806-14.
30. Sen-Chowdhry S, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52(25):2175-87.
31. Quarta G, et al. Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. Circulation. 2011;123(23):2701-9.
32. Xu T, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2010;55(6):587-97.
33. Sen-Chowdhry S, et al. Mutational heterogeneity, modifier genes, and environmental influences contribute to phenotypic diversity of arrhythmogenic cardiomyopathy. Circ Cardiovasc Genet. 2010;3(4):323-30.
34. Maron BJ, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-16.
35. Zaragoza MV, Arbustini E, Narula J. Noncompaction of the left ventricle: primary cardiomyopathy with an elusive genetic etiology. Curr Opin Pediatr. 2007;19(6):619-27.
36. Bleyl SB, et al. Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am J Hum Genet. 1997;61(4):868-72.
37. Hoedemaekers YM, et al. The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy. Circ Cardiovasc Genet. 2010;3(3):232-9.
38. Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of restrictive cardiomyopathy. Heart Fail Clin. 2010;6(2):179-86.
39. Fitzpatrick AP, et al. Familial restrictive cardiomyopathy with atrioventricular block and skeletal myopathy. Br Heart J. 1990;63(2):114-8.
40. Mogensen J, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest. 2003;111(2):209-16.
41. Caleshu C, et al. Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy. Am J Med Genet A. 2011;155A(9):2229-35.
42. Ware SM, et al. Pediatric restrictive cardiomyopathy associated with a mutation in beta-myosin heavy chain. Clin Genet. 2008;73(2):165-70.
43. Kaski JP, et al. Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart. 2008;94(11):1478-84.
44. Meder B, et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet. 2011;4(2):110-22.
45. Van Driest SL, et al. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(9):1903-10.
46. Richard P, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107(17):2227-32.
47. Girolami F, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol. 2010;55(14):1444-53.
48. Ashley EA, et al. Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2012;126(1):142-57.
49. Caleshu C, et al. Use and interpretation of genetic tests in cardiovascular genetics. Heart. 2010;96(20):1669-75.
50. Washington, U.o. GeneTests. [cited 2012 9/10/12]; Available from: genetests.org.
51. National Center for Biotechnology Information, U.S.N.L.o.M. Genetic Testing Registry. 2012 [cited 2012 9/10/12]; Available from: http://www.ncbi.nlm.nih.gov/gtr/.
52. • Ingles J, et al. A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart. 2012;98(8):625-30. This study shows that predictive genetic testing is highly cost-effective in HCM families compared to clinical screening alone.
53. Lakdawala NK, et al. Genetic testing for dilated cardiomyopathy in clinical practice. J Card Fail. 2012;18(4):296-303.
54. Ho CY. Hypertrophic cardiomyopathy in 2012. Circulation. 2012;125(11):1432-8.
55. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319):1061-73. http://www.ncbi.nlm.nih.gov/pubmed/20981092.
56. Tennessen JA, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64-9.
57. • Golbus JR, et al. Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet. 2012;5(4):391-9. By querying the 1000 Genomes Project database, this study showed that the frequency of predicted pathogenic variants in genes associated with cardiomyopathies was higher than expected based on known cardiomyopathy prevalence data.
58. Kapplinger JD, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol. 2011;57(23):2317-27.
59. Resta R, et al. A new definition of Genetic Counseling: National Society of Genetic Counselors' Task Force report. J Genet Couns. 2006;15(2):77-83.
60. Cowan J, et al. Genetic testing and genetic counseling in cardiovascular genetic medicine: overview and preliminary recommendations. Congest Heart Fail. 2008;14(2):97-105.
61. Gersh BJ, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212-60.
62. Morales A, et al. Family history: an essential tool for cardiovascular genetic medicine. Congest Heart Fail. 2008;14(1):37-45.
63. Kuliev A, et al. PGD for inherited cardiac diseases. Reprod Biomed Online. 2012;24(4):443-53.
64. Hershberger RE. Cardiovascular genetic medicine: evolving concepts, rationale, and implementation. J Cardiovasc Transl Res. 2008;1(2):137-43.
65. • Aatre RD, Day SM. Psychological issues in genetic testing for inherited cardiovascular diseases. Circ Cardiovasc Genet. 2011;4(1):81-90. This is an outstanding review of the issues patients face from a psychological standpoint when undergoing genetic testing for heritable heart diseases.
66. van der Roest WP, et al. Family letters are an effective way to inform relatives about inherited cardiac disease. Am J Med Genet A. 2009;149A(3):357-63.